Furthermore, evidence of increased eIF4E-ser209 phosphorylation in both BOS and RAS human MCs and the inhibition of bronchovascular bundle fibrosis by MNK inhibitors, a key component of both BOS and RAS phenotypes, suggests the wider relevance of clinically targeting this pathway in CLAD. This evidence concerns the gene ATP7A and Buschke-Ollendorff syndrome.